The Limbic

Antibiotics don’t impair chemo-immunotherapy efficacy in lung cancer

While antibiotics may impair the efficacy of immune checkpoint inhibitors, the detrimental effect does not extend to chemo-immunotherapy combinations in patients with lung cancer, new research shows. An international multicentre study involving 302 patients with stage IV NSCLC found no effect...

While antibiotics may impair the efficacy of immune checkpoint inhibitors, the detrimental effect does not extend to chemo-immunotherapy combinations in...

Fine tuning required before lung cancer screening can proceed: Aussie experts

Antibiotics don’t impair chemo-immunotherapy efficacy in lung cancer

Respiratory physicians call for national lung cancer Clinical Quality Registry to address inequalities

Adjuvant immunotherapy the new standard of care in patients with resected, early-stage NSCLC?

Thoracic Oncology Group of Australasia (TOGA) inaugural meeting highlights: Dr Emily Stone

Socioeconomic status a barrier to lung cancer treatment

Some lung cancer patients may not be fit for immunotherapy: Australian study

Mesothelioma patients gain PBS access to dual immunotherapy

First targeted therapy approved to prevent recurrence of early stage NSCLC

Funding for lung cancer nurses a ‘breakthrough’: Dr Vanessa Brunelli

New treatment option approved for patients with early stage NSCLC

Memorial Fund set up for oncologist who died of lung cancer at 40

First steps on national lung cancer screening program to begin in July

Lung cancer top of the list for assisted dying

Breath test better than low dose CT for lung cancer screening

Why physicians should be ‘driving instructor’ when it comes to opioids: Natasha Smallwood

PD-L1 points to poor outcomes in EGFR lung cancer

Lung cancer screening widened to target younger smokers

Less ‘harm’ from lung cancer screening than trials suggested

Older therapy is new maintenance option for patients with mesothelioma

KRAS inhibition comes of age for lung cancer?

National lung cancer screening program recommended in report

TSANZ says new evidence strengthens case against vaping for smoking cessation

Real world lung cancer screening adherence is lower than trial rates

Screening reveals high rates of early stage silicosis in stone workers

Lung cancer overtaken by dementia as second leading cause of death in males

New TSANZ guidance on respiratory surveillance for dust diseases

Lung screening is coming to Australia – the question is in what form

Why lung cancer patients don’t receive guideline recommended therapy

Lung cancer screening evidence contested at ERS 2020

ALK inhibitor suitable for first line therapy in NSCLC

Advanced mesothelioma: frontline chemoimmunotherapy shows promise in DREAM trial

Assisted dying scheme needs more respiratory specialists on board

Lung cancer patients with COVID-19 have 36% mortality rate: TERAVOLT

Lessons from NELSON study: implementation trials the next step in lung cancer screening

First positive results for dual immunotherapy in mesothelioma

Lung cancer detected at earlier stage with biomarker-based screening

Biomarker blood test may detect earlier stage disease in lung cancer screening

Dual immunotherapy approved for NSCLC

TSANZ comes out strongly against e-cigarettes

Lung cancer research faces shake-up after dramatic split of ALTG

KRAS mutation targetable for better outcomes in smokers with NSCLC

Lung cancer outcomes gap still wide for Indigenous Australians

Call for lung cancer specialist nurse funding

Osimertinib could be new standard of care for EGFRm NSCLC

A/Prof Nick Pavlakis: how lung cancer care has changed in the COVID-19 pandemic

Lung cancer linked to higher mortality in COVID-19

Lung cancer conference: Associate Professor Nick Pavlakis on the steps to improving care

ALCC 2020: Lung cancer screening works – it’s time to do it

Case for targeted lung cancer screening bolstered by NELSON results, experts say

PBS broadens access to COPD triple therapy and lung cancer immunotherapy

Vaping backed for smoking cessation in ‘pragmatic’ new RACGP guidelines

National Dust Disease Taskforce’ advice slammed as lacking urgency

Lung Foundation seeks help to counter Big Tobacco’s latest toxic product

Active case finding urgently needed for silicosis epidemic: TSANZ

Disappointing results for mesothelioma trial

Atezolizumab shows OS benefit over chemo in PD-L1 high NSCLC

First KRAS-targeted therapy for lung cancer shows promise

Vaping-NRT combination boosts smoking quit rates

Warning of normal X-rays in silicosis patients

Minister requests feasibility study for lung cancer screening

Start date announced for National Dust Disease Taskforce

Lung cancer: personalised medicine to be delivered by ‘molecular champions’

Silicosis patients also at risk of scleroderma

PBS allows unrestricted pemetrexed use in first-line treatment of NSCLC

‘Non-expandable lung’ common finding in mesothelioma patients

Atezolizumab-based combination gets first line approval for metastatic NSCLC

1 in 4 patients with advanced NSCLC alive at 5 years with immunotherapy

Infographic shows modern day benefits and harms of lung cancer screening

National Dust Diseases Taskforce to be set up this year

Respiratory physician wins case against asbestos industry lobbyist

Professor Ian Yang: exploring coexisting COPD and lung cancer

Advanced lung cancer patients get real benefits from home exercise support

Functional decline at end of life shows ‘tipping point’ in respiratory patients

Woolcock’s lung cancer centre leader looks to microbiome

Room to improve care for stage lll NSCLC

RACP calls for urgent action on dust diseases recommendations

SABR the treatment of choice for inoperable stage 1 NSCLC

$4 million launch for National Strategic Action Plan for Lung Conditions

Lung cancer still diagnosed in emergency settings

GPs unlikely to pick up certain cancers right away because its not the most likely diagnosis